Supported by the VA grant CDA IK2RX003407-01A1, Race to Erase MS Innovation award, National Institutes of Health (NIH) NIH grants R01 EY023285, R21 EY032146, P30 EY010572, P30 EY010572 core grant, the Malcolm M. Marquis, MD Endowed Fund for Innovation, and an unrestricted grant from Research to Prevent Blindness to Casey Eye Institute. The sponsor or funding organization had no role in the design or conduct of this research.
Disclosure: P.-H. Yeh, None; O. Tan, Visionix/Optovue (P, R); E. Silbermann, None; E. White, None; D. Choi, None; A. Chen, None; E. Ing, None; D. Bourdette, None; J. Wang, Visionix/Optovue (P, R), Genentech (P, R); Y. Jia, Visionix/Optovue (P, R), Optos (P), Genentech (P, R, F); D. Huang, Visionix/Optovue (F, P, R), Boehringer Ingelheim (C), Canon (F), Cylite (F), Intalight (F), Genentech (P, R), Kugler (R)